April 19, 2023 – Intermountain Precision Genomics Laboratory received certification from the New York State Department of Health Clinical Laboratory Evaluation Program. Intermountain Precision Genomics, a service of Intermountain Health, and partner Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, are now certified to offer solid tumor testing to patients in all 50 U.S. states after receiving the New York State Clinical Laboratory Permit. This achievement follows a recent site inspection as part of the New York State Department of Health Clinical Laboratory Evaluation Program.
Intermountain Precision Genomics’ TheraMap®: Solid Tumor genomic test, also offered by Myriad as Precise™ Tumor, analyzes a patient’s tumor DNA to discover what changes, or gene mutations, are causing the cancer. Specialists apply the results to recommend a targeted treatment plan for the patient’s unique tumor profile.
In 2021, Intermountain Health and Myriad announced a collaboration on a comprehensive offering of tests, which includes TheraMap/Precise Tumor. The suite, known as Precise Oncology Solutions, provides oncologists with a complete genetic analysis combining somatic tumor profiling, tissue analysis, and germline testing into one report – helping them establish individualized treatment options for each patient.
TheraMap is the first test in Intermountain Precision Genomics history to obtain this certification. Myriad Genetics was previously certified by the New York State Department of Health for its MyRisk® Hereditary Cancer test and somatic tumor profiling MyChoice® CDx test.